Form 4: Assembly Biosciences CEO Sells Shares to Cover Tax Obligations
SEC Form 4
Assembly Biosciences CEO Jason A. Okazaki sold 197 shares of common stock on October 3, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On October 3, 2024, Jason A. Okazaki, CEO and President of Assembly Biosciences, sold 197 shares of common stock at a price of $14.81 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units.
- This transaction was mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors, requiring a 'sell-to-cover' transaction for tax obligations.
- Following the transaction, Okazaki directly owns 14,904 shares of Assembly Biosciences common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future.
Stakeholder Impact
- The sale of a small number of shares is unlikely to have a significant impact on shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Date of stock sale transaction |
| 10/04/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.